[go: up one dir, main page]

MX2019009351A - Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer. - Google Patents

Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer.

Info

Publication number
MX2019009351A
MX2019009351A MX2019009351A MX2019009351A MX2019009351A MX 2019009351 A MX2019009351 A MX 2019009351A MX 2019009351 A MX2019009351 A MX 2019009351A MX 2019009351 A MX2019009351 A MX 2019009351A MX 2019009351 A MX2019009351 A MX 2019009351A
Authority
MX
Mexico
Prior art keywords
cancer
heteroarylsulfonyl
treatment
substituted pyridines
compounds
Prior art date
Application number
MX2019009351A
Other languages
Spanish (es)
Other versions
MX392000B (en
Inventor
Suna Edgars
Pelcman Benjamin
Stafford William
Priede Martins
Original Assignee
Oblique Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblique Therapeutics Ab filed Critical Oblique Therapeutics Ab
Publication of MX2019009351A publication Critical patent/MX2019009351A/en
Publication of MX392000B publication Critical patent/MX392000B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan compuestos de la Fórmula I (I) (ver formula I) o sales aceptables desde el punto de vista farmacéutico de estos, en donde L, 10 R1, R2, R3 y X tienen significados proporcionados en la descripción, en donde los compuestos son útiles en el tratamiento de tipos de cáncer.Compounds of Formula I (I) (see Formula I) or pharmaceutically acceptable salts thereof are provided, wherein L, R1, R2, R3 and X have meanings provided in the description, wherein the compounds they are useful in treating types of cancer.

MX2019009351A 2017-02-07 2018-02-07 HETEROARYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN CANCER TREATMENT. MX392000B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762455639P 2017-02-07 2017-02-07
US201762594799P 2017-12-05 2017-12-05
PCT/GB2018/050343 WO2018146469A1 (en) 2017-02-07 2018-02-07 Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2019009351A true MX2019009351A (en) 2019-09-19
MX392000B MX392000B (en) 2025-03-21

Family

ID=61226606

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009351A MX392000B (en) 2017-02-07 2018-02-07 HETEROARYLSULFONYL-SUBSTITUTED PYRIDINES AND THEIR USE IN CANCER TREATMENT.

Country Status (12)

Country Link
US (1) US11028067B2 (en)
EP (1) EP3580215A1 (en)
JP (1) JP2020507625A (en)
KR (1) KR20190115013A (en)
CN (1) CN110382486A (en)
AU (1) AU2018218519B2 (en)
BR (1) BR112019016223A2 (en)
CA (1) CA3051537A1 (en)
MA (1) MA47451A (en)
MX (1) MX392000B (en)
WO (1) WO2018146469A1 (en)
ZA (1) ZA201904967B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
CN110382465A (en) 2017-02-07 2019-10-25 欧比力克治疗公司 Sulfinyl pyridine and its purposes in cancer treatment
EP3580209A1 (en) 2017-02-07 2019-12-18 Oblique Therapeutics AB Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
CN110382464A (en) 2017-02-07 2019-10-25 欧比力克治疗公司 The pyridine and its purposes in cancer treatment that alkylsulfonyl replaces
JP2021513573A (en) * 2018-02-12 2021-05-27 シンダ ファーマ エービー Thioredoxin reductase inhibitor used to treat cancer
FI3853234T3 (en) 2018-09-18 2025-07-28 Nikang Therapeutics Inc Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3064846D1 (en) * 1979-12-19 1983-10-20 Duphar Int Res New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds
US4456469A (en) 1980-03-07 1984-06-26 E. I. Du Pont De Nemours And Company Pyridyl sulfone herbicides
AU543161B2 (en) 1980-03-07 1985-04-04 E.I. Du Pont De Nemours And Company Pyrimidine or s.triazine derivatives
US4791127A (en) 1985-10-07 1988-12-13 Nippon Kayaku Kabushiki Kaisha Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides
DE3812177A1 (en) 1988-04-13 1989-10-26 Bayer Ag 2-PHENYLSULFINYL-NITRO-PYRIDINE, METHOD FOR THE PRODUCTION AND THEIR USE
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
US6069144A (en) 1995-08-24 2000-05-30 Basf Aktiengesellschaft N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications
DE19531148A1 (en) 1995-08-24 1997-02-27 Basf Ag New and known substd. alkylthio-pyridine derivs.
EP0984935A1 (en) 1997-05-30 2000-03-15 Basf Aktiengesellschaft Method for producing substituted thiopyridines
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
AU9781098A (en) 1997-10-02 1999-04-27 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6191170B1 (en) 1998-01-13 2001-02-20 Tularik Inc. Benzenesulfonamides and benzamides as therapeutic agents
DE69906397T2 (en) 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003211427A1 (en) 2002-02-18 2003-09-04 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
WO2005121121A2 (en) 2004-06-04 2005-12-22 Arena Pharmaceuticals, Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20060019967A1 (en) 2004-07-21 2006-01-26 Su-Ying Wu SARS CoV main protease inhibitors
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
WO2006083692A2 (en) 2005-01-28 2006-08-10 Mount Sinai Schoool Of Medicine Methods of identifying modulators of bromodomains
GB0504828D0 (en) 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
US20100048713A1 (en) 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
JP2009535307A (en) 2006-04-28 2009-10-01 アベキサ・リミテッド Integrase inhibitor 3
EP2061472A4 (en) * 2006-05-22 2010-12-22 Thioredoxin Systems Ab Bacterial thioredoxin reductase inhibitors and methods for use thereof
MX2010000617A (en) 2007-07-17 2010-05-17 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor.
CN101723932B (en) 2008-10-31 2013-11-20 北京以岭生物工程技术有限公司 Nitropyridine ethylenimine compound, medicinal composition, preparation method and application thereof
US9421211B2 (en) * 2009-05-28 2016-08-23 President And Fellows Of Harvard College N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation
NZ713361A (en) 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US9206125B2 (en) 2010-02-10 2015-12-08 Public University Corporation Yokohama City University Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF)
CN102206172B (en) 2010-03-30 2015-02-25 中国医学科学院医药生物技术研究所 Substituted diaryl compound and preparation method and antiviral application thereof
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
CN104220053B (en) 2012-02-10 2017-05-03 德克萨斯大学系统董事会 Modulators of exchange proteins directly activated by camp (epacs)
US8946418B1 (en) 2013-07-10 2015-02-03 Boehringer Ingelheim International Gmbh Chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes
CN104672214B (en) 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 Compound and its preparation and purposes with ALK inhibitory activity
CN105503827B (en) 2014-10-11 2019-09-24 上海翰森生物医药科技有限公司 EGFR inhibitor and its preparation method and application
CN105085483B (en) 2015-06-04 2019-01-01 湖北生物医药产业技术研究院有限公司 Kinase inhibitor and its application
CN104987324B (en) 2015-06-04 2018-05-04 湖北生物医药产业技术研究院有限公司 Pyrimidine derivatives as ALK inhibitor
GB201514021D0 (en) 2015-08-07 2015-09-23 Arner Elias Set Jeno Novel Pyridines and their use in the treatment of cancer
CN110382464A (en) 2017-02-07 2019-10-25 欧比力克治疗公司 The pyridine and its purposes in cancer treatment that alkylsulfonyl replaces
EP3580209A1 (en) 2017-02-07 2019-12-18 Oblique Therapeutics AB Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer
CN110382465A (en) 2017-02-07 2019-10-25 欧比力克治疗公司 Sulfinyl pyridine and its purposes in cancer treatment

Also Published As

Publication number Publication date
CN110382486A (en) 2019-10-25
EP3580215A1 (en) 2019-12-18
JP2020507625A (en) 2020-03-12
AU2018218519A1 (en) 2019-08-15
ZA201904967B (en) 2023-12-20
RU2019128045A (en) 2021-03-09
US20200223819A1 (en) 2020-07-16
AU2018218519B2 (en) 2021-08-05
KR20190115013A (en) 2019-10-10
CA3051537A1 (en) 2018-08-16
WO2018146469A1 (en) 2018-08-16
US11028067B2 (en) 2021-06-08
MX392000B (en) 2025-03-21
MA47451A (en) 2019-12-18
BR112019016223A2 (en) 2020-04-07
RU2019128045A3 (en) 2021-03-09

Similar Documents

Publication Publication Date Title
MX2019009354A (en) Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer.
ECSP19033052A (en) PYRAZOLE [1,5-A] PYRIDINE COMPOUNDS SUBSTITUTED AS INHIBITORS OF RET KINASE
MX2019009351A (en) Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer.
ECSP19032676A (en) PYRAZOLE [1,5-A] PYRIDINE COMPOUNDS SUBSTITUTED AS INHIBITORS OF RET KINASE
MX2019009266A (en) PYRIDINES SUBSTITUTED WITH HYDROCARBYLSULFONIL AND ITS USE IN THE TREATMENT OF CANCER.
CY1125214T1 (en) N-((ET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDE COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS
CO2018011064A2 (en) Bromodomain Inhibitors
CY1124187T1 (en) HETEROCYCLIC AMIDES AS KINASE INHIBITORS
CY1123592T1 (en) AURORA A KINASE INHIBITOR
GEAP202215535A (en) Compounds
MX2018001576A (en) Pyridines and their use in the treatment of cancer.
CY1124173T1 (en) SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF THERAPY THEREOF
MX2018004643A (en) Benzolactam compounds as protein kinase inhibitors.
MX390537B (en) IMIDAZOLONYLQUINOLINES AND THEIR USE AS ATM KINASE INHIBITORS
MX2018002402A (en) Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators.
NI201600152A (en) FUSED BICYCLIC HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS
CL2020000363A1 (en) Macrocyclic mcl-1 inhibitors and methods of use.
CY1120907T1 (en) ANTI-FUNGAL AGENTS
EA201992320A1 (en) PIPERIDINES AS COVALENT MENIN INHIBITORS
MX2018008362A (en) DERIVATIVES OF QUINOLIN-2-ONA.
PE20181346A1 (en) IMIDAZO [4,5-C] QUINOLIN-2-ONA COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
MX2015012896A (en) Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors.
PE20191486A1 (en) DEUTERATED IMIDAZO [4,5-c] QUINOLIN-2-ONA TYPE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CY1124751T1 (en) COMBINATION TREATMENTS INVOLVING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES
MX2021009426A (en) Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer.